Abstract:Graphical and Lay Summary Recombinant adeno‐associated virus (rAAV) is a widely used gene delivery vehicle for human gene therapies, but large‐scale rAAV manufacturing using plasmid transfection and virus infection faces challenges such as cost and inefficiency. This study presents an innovative platform by enhancing previously developed synthetic rAAV producer cell lines. These high‐producing cell lines were integrated with all essential viral components and supplemented with additional copies of the cap gene. They not only generated rAAV with high titers upon induction but also achieved high full‐to‐empty particle ratios by tuning capsid formation through inducer concentrations and induction time profiles. Recombinant adeno‐associated virus (rAAV) is widely used as an in vivo delivery vector for gene therapy. It is used in a very large dose, and the large quantities required for broad applications present manufacturing challenges. We have developed a synthetic biology platform of constructing cell lines integrated with essential viral genes which can be induced to produce rAAV without plasmid transfection or virus transduction. Through iterative design‐construct‐characterization cycles, we have showcased the potential of this synthetic cell production system. Systems characterization of the dynamics of viral transcripts and proteins as well as virus assembly and packaging revealed that the expression level and balance of viral genome and capsid protein are keys to not only the productivity but also the full particle content, an important product quality attribute. Boosting cap gene expression by sequential transfection and integration of multiple copies of the cap gene elevated the rAAV titer to levels on a par with traditional plasmid transfection and virus infection. However, overexpression of the cap gene shifted the balance and kinetics of the genome and capsid. We independently tuned the dynamics of genome amplification and capsid protein synthesis by modulating the induction concentration as well as the time profile, and significantly enhanced full particle content while maintaining a high productivity. This strategy of constructing an inducible stable producer cell line is readily adaptable to rAAV vectors of different serotypes and payloads. It can greatly facilitate scalable production of gene therapy vectors.

Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators as enhancers of AAV production

Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

Multi‐omics kinetic analysis of recombinant adeno‐associated virus production by plasmid transfection of HEK293 cells

Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells

Tuning capsid formation dynamics in recombinant adeno‐associated virus producing synthetic cell lines to enhance full particle productivity

Comparative transcriptomic and proteomic kinetic analysis of adeno-associated virus production systems

CRISPR screen for rAAV production implicates genes associated with infection

Enhancement of rAAV titers via inhibition of the interferon signaling cascade in transfected HEK293 suspension cultures

Multidose transient transfection of human embryonic kidney 293 cells modulates recombinant adeno-associated virus2/5 Rep protein expression and influences the enrichment fraction of filled capsids

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Proteome profiling and vector yield optimization in a recombinant adeno‐associated virus‐producing yeast model

Enhanced ER protein processing gene expression increases rAAV yield and full capsid ratio in HEK293 cells

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing

The state of technological advancement to address challenges in the manufacture of rAAV gene therapies

Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platforms

Comprehensive mRNA‐sequencing‐based characterization of three HEK‐293 cell lines during an rAAV production process for Gene Therapy Applications

A Direct Comparison of rAAV5 Variants Derived from the Baculovirus Expression System Using LC-MS Workflows Demonstrates Key Differences in Overall Production Yield, Product Quality and Vector Efficiency

Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells